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doi:10.1016/j.kjms.2011.10.004Abstract This study investigates the expression of annexin 1 in urothelial carcinoma (UC) and
its relation with clinicopathologic factors, and evaluates its potential clinical significance.
Annexin 1 expression was analyzed by immunohistochemical staining with manual tissue micro-
arrays and Western blot in UC. Immunohistochemical analysis of UC in tissue microarrays
showed that annexin 1 protein was 76.5% (150/196) positive, which was markedly increased
compared with that in the normal urothelium 20.8% (5/24) (p < 0.01). In addition, the positive
expression rate of annexin 1 was higher in the high-grade UC (81.7%; 143/175) than in the
low-grade UC (33.3%; 7/21). Western blot revealed that the expression of annexin 1 was low
in low-grade UC, and markedly increased in high-grade UC. In conclusion, annexin 1 overex-
pression is observed in UC, which suggests it may be associated with tumorigenesis and its
expression correlates with the differentiation of UC.
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Significant improvements in gene and protein expression
analysis mean that most researchers have greater oppor-
tunities to study and understand events responsible for
human cancer development. It is important that useful
molecular information from relevant tissue samples anded.
146 W.-Y. Kang et al.from efficient analysis of vast genomic and proteomic
databases is obtained. With the development of molecular
profiling techniques, numerous key gene and protein
expressions associated with cancer proliferation and
progression are identified, enabling researchers and clini-
cians to find better ways to treat disease.
Urinary bladder cancer is the most prevalent type of
cancer worldwide to occur in the urinary tract and an
estimated 290,000 new cases are diagnosed each year in
men and 88,000 in women [1]. In Taiwan, cancer of the
urinary bladder accounted for approximately 735 deaths in
2010 [2]. Urothelial carcinoma (UC) of renal pelvis and
ureter, also known as upper UC, is uncommon throughout
most of the world but the incidence is unusually high in
Taiwan [3,4]. It has also been reported that approximately
42% of patients with upper UC had associated bladder
cancer [5].
Annexin 1, also known as lipocortin-1 or calpactin II, is
a 38 kDa protein that is one of the 20 members of the
annexin family of calcium and phospholipid-binding
proteins. These members share a common core domain
harboring the Ca2þ- and phospholipid-binding sites but each
has a unique N-terminal tail that imparts its functional
specificity [6]. It is thought that phosphorylation of this
region regulates specific biological actions of annexin 1. It
has been suggested to have a biological role in inhibiting
the activity of phospholipase A2 and a role as a substrate
for epidermal growth factor receptor (EGFR) [6]. In addi-
tion, it may be a crucial mediator of apoptosis, intracellular
calcium release and membrane trafficking [7,8]. Structur-
ally, annexin 1 is a component of the cornified envelope and
may play an important role in keratinization [9]. Other
functions of annexin 1 include regulation of hepatocyte
growth factor receptor signaling, facilitation of epidermal
growth factor degradation, and control of intracellular
calcium release [10,11]. Overexpression of annexin 1 was
found in some epithelial malignancies including gastric and
breast cancer [12]. Downregulation of annexin 1 protein
expression is a common finding in high-grade prostatic
intraepithelial neoplasm and prostate cancer [13]. Loss of
annexin 1 protein expression may be involved in the
development of esophageal squamous cell carcinoma [14].
These findings suggested that dysregulation of annexin 1
protein may be associated with the development of human
cancer.
In this investigation, we demonstrate annexin 1 protein
expression in UC compared with the normal urothelium




A total of 196 cases were collected from routinely pro-
cessed paraffin-embedded material from renal pelvis (77),
ureter (56) and urinary bladder (63) including infiltrating
UC and noninvasive UC, and each group was divided into
a low- and high-grade subgroup. The criteria of low- and
high-grade and TNM stage of UC were defined according
to the most recent World Health Organization criteria [15].All tissue materials were selected after histological review
from the archives of the Department of Pathology, Kaoh-
siung Medical University Chung-Ho Memorial Hospital
between 1991 and 2000. The median age of these patients
at diagnosis was 63.5 years (range, 21e87 years). This
study was approved by the Institutional Review Board of
Kaohsiung Medical University Hospital (reference number
KMUH-IRB-960028). The tissue microarray (TMA) was con-
structed using formalin-fixed paraffin-embedded UC tissue
samples. The original slides were reviewed by two pathol-
ogists (W.-Y. Kang and C.-Y. Chai) using the latest World
Health Organization classification. Slides containing the
representative area of the tumor were circled in color ink.
For each case, one core of the tumor (2.0 mm in diameter)
was carefully transferred with forceps from the selected
areas to the recipient metal paraffin block box. Four-
micrometer sections of the TMA block were cut and stained
with hematoxylin-eosin to verify that the cores adequately
represented diagnostic areas.
In addition, 24 urothelial epithelia were obtained from
patients who did not suffer from urothelial tumor including
seven from the renal pelvis, 12 from the ureter and five
from the bladder.
Fresh tissue samples of five high-grade and five low-grade
UCs were obtained after resection during 2001 to 2006.
Tumors were sampled and stored at 140C and the residual
parts of specimens were fixed with 10% formalin for histo-
logical diagnosis. Histological diagnosis of these samples
was all UC. None had received preoperative radiotherapy
or chemotherapy.
TMA construction and IHC analysis
The hematoxylin-eosin slides were examined under a light
microscope. The representative area of each donor block
was circled in color ink. A biopsy needle was used to
acquire cylindrical core tissue biopsies with a diameter of
2 mm from a histologically representative area of each
donor block. The cylindrical core tissues were carefully
transferred with forceps to a recipient metal paraffin block
box. One recipient box could accommodate 56 (8  7)
cylinders. One normal tissue core was arranged at one
corner of the block for the purpose of internal control and
proper orientation of the tissue matrix. After all the
cylinders were aligned in the box, the box was covered with
a plastic cassette, and then liquid wax was gently poured
into the box until it was full. Then the box was cooled to
room temperature slowly. Before sectioning, the tissue
array paraffin block was chilled to 4C and removed from
the box. Four-micrometer sections were cut using an ordi-
nary microtome, and the sections were mounted on plain
slides for hematoxylin-eosin staining, and then they were
placed on silane-coated slides for IHC.
IHC analysis using the streptavidin-biotin method was
utilized to detect annexin 1. In brief, sections were
deparaffinized and autoclave-treated at 121C for
8 minutes in 0.1 M citrate buffer (pH 6.0). Endogenous
peroxidase in the section was blocked by incubation in 3%
hydrogen peroxide for 5 minutes at room temperature.
After washing with Tris buffer solution and incubation with
5% bovine serum albumin for 2 hours, the sections were
Table 1 Correlation of annexin 1 expression with clini-




rate of annexin 1(%)
p
Histological grade
High 175 81.7 (143/175) <0.001
Low 21 33.3 (7/21)
T stage
Ta 49 61.2 (30/49) 0.272
T1 25 76.0 (19/25)
T2 40 82.5 (33/40)
T3 77 84.4 (65/77)
T4 5 60.0 (3/5)
Lymph node metastasis
Yes 7 57.1 (4/7) 0.120
No 189 77.2 (146/189)
Location
Upper urinary tract 133 74.4 (99/133) 0.175
Lower urinary tract 63 80.9 (51/63)
Annexin 1 in urothelial carcinoma 147incubated with the primary antibodies annexin 1 (BD-
610066, 1:1000; BD Transduction Lab) and were applied at
room temperature for 50 minutes. Biotinylated second
antibody and peroxidase-conjugated streptavidin from the
DAKO Universal LSAB kit (DAKO, Denmark) were applied for
20 minutes each. Finally, sections were incubated in 3,3’-
diaminobenzidine for 5 minutes, followed by hematoxylin
counterstaining and mounting. Negative controls were ob-
tained by replacing the primary antibody with nonimmune
serum while known immunostaining-positive slides were
used as positive controls.
The level of annexin 1 expression was calculated by
combining an estimate of the percentage of immunoreac-
tive cells with the staining intensity (staining intensity
score) as previously described [16]. No staining was scored
as 0, 1e10% as 1, 11e50% as 2, 51e70% as 3, and 71e100% as
4. Staining intensity was evaluated as follows: 0Z negative
(no color), 1Z weak (weak brown), 2Zmoderate (brown),
and 3Z strong (dense brown). The IHC score was obtained
by multiplying the percentage of positive cells and staining
intensity. The scores ranged from 0 to 12. An IHC score
greater than 3 was considered to be a positive expression.
Two pathologists (W.-Y. Kang and C.-Y. Chai) blind to the
clinical outcome independently evaluated the immunostain-
ing patterns. If a discrepancy was present, the pathologists
reanalyzed the slides together and reached a consensus
regarding the final score.
Western blot analysis
Ten micrograms of protein extracts of UC tissues from 10
different patients including five high-grade and five low-
grade UCs were prepared for Western blot analysis. All
fresh samples were prepared on an extraction buffer con-
taining 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl,
10 g/L Triton-100, 1 g/L SDS, 1 mmol/L EDTA, 1 mmol/L
AEBSF, and 20 mg/mL leupeptin. After centrifugation at
12000 rpm for 20 minutes at 4C, the supernatant was
collected. Equal amounts of total protein from each sample
were loaded and separated by SDS-polyacrylamide gel
electrophoresis, and then transferred to polyvinylidenedi-
fluoride membrane. After being blocked with 5% nonfat
dried milk in Tris buffer solution (pH 7.4) with Tween-20,
the membrane was probed with the anti-annexin 1 mouse
monoclonal primary antibody (1:5000 dilution, BD Biosci-
ences Pharmingen, Chicago, IL). Secondary antibody was
conjugated with horseradish peroxidase (Cell Signaling
Technology, USA). Annexin 1 was visualized by enhanced
chemiluminescence (Amersham, Buckinghamshire, England);
this antibody could detect specific bands migrating at
38-kDa. Parallel Western blot was probed with the anti-
glyceraldehyde-3-phosphate dehydrogenase monoclonal
antibody (GAPDH) (Cell Signaling Technology, USA) as an
internal control.
Statistical analysis
Statistical analysis was performed using the SPSS 8.0 soft-
ware program (Chicago, IL, USA). The annexin 1 expression
in different groups was analyzed using the ManneWhitney
U test whereas the correlation between annexin 1 and eachclinicopathologic factor was assessed with Spearman rank
correlation test. A p value of less than 0.05 was considered
statistically significant.
Results
Expression of annexin 1 in normal urothelia and UC
Of 24 normal urothelia and 196 UCs, annexin 1 was found
positive in five normal (20.8%) and in 150 UCs (76.5%). All
196 carcinomas were divided into two groups, infiltrating
urothelial carcinomas and noninvasive carcinomas: 120
(81.6%) cases of infiltrating carcinomas and 30 (61.2%) cases
of noninvasive carcinomas showed positive expression of
annexin 1. A low positive expression rate of annexin 1 in
normal urothelia was found; in contrast, positive expression
of annexin 1 in UCs was upregulated significantly (p < 0.01).
Expression of annexin 1 also showed no difference between
infiltrating UC and noninvasive UC.
Correlation of annexin 1 expression with
clinicopathologic factors of UC
Histological differentiation
Table 1 shows that 143 out of 175 high-grade UCs revealed
positive expression of annexin 1, whereas 7 out of 21 low-
grade UCs had positive results. Fig. 1 demonstrates that
positive annexin 1 expression was statistically higher in
high-grade UC than in low-grade UC.
T stage, Lymph nodes status and upper versus lower UC
There were no statistically significant correlations between
annexin 1 expression and T stage, the depth of tumor
invasion or the status of lymph nodes metastases. Also,
there was no difference of expression of annexin 1 in upper
UC compared with lower UC (Table 1).
Figure 1. Immunohistochemical staining demonstrating negative expression of annexin 1 in low-grade urothelial carcinoma (A, B)
whereas positive expression was observed in high-grade urothelial carcinoma (C, D). Original magnification: A, C: 40; B, D: 200.
Figure 2. (A) Annexin 1 expression is high in high-grade
urothelial carcinoma (lanes 1, 2) and low in low-grade uro-
thelial carcinoma (lanes 3, 4). Lane 2 also shows 38 and 34 kDa
isoforms; (B) densitometric analysis for annexin 1 in high-grade
and low-grade urothelial carcinoma.
148 W.-Y. Kang et al.Western blot analysis of annexin 1 expression
Western blot revealed that the expression of annexin 1
was low in low-grade UC whereas the level of annexin 1
expression markedly increased in high-grade UC. The
intensity of annexin 1 expression was measured by
densimeter as 453.517 in low-grade UC and 1050.040 in
high-grade carcinoma. A high-grade UC also appeared as
a doublet (38 and 34-kDa bands) (Fig. 2), and such findings
are consistent with a previous study showing annexin 1
isoform expression [17].
Discussion
The expression of annexin 1 was evaluated in tissue samples
derived from patients with UC by using the immunohisto-
chemistry with a manual TMA as well as Western blot. We
showed that high annexin 1 expression in UC was associated
with tumor grade but there was no difference between
tumor stage and the presence of lymph node metastasis.
Previous studies have shown both upregulation and down-
regulation of annexin 1 in a variety of malignancies;
however, as yet there is no consensus on the mechanism of
how annexin 1 influences tumor initiation and/or progres-
sion. Annexin 1 may have a tissue-specific effect in tumor
carcinogenesis. Upregulated annexin 1 was also found in
a drug-resistant stomach cancer cell line, pituitary carci-
noma, hairy cell leukemia, hepatocellular carcinoma, and
breast cancer [12,18e21].
The annexin family is composed of a group of structur-
ally related calcium-binding proteins. All these proteinshave a conserved domain (so-called annexin domain) in
common that binds to phospholipids. Every annexin has
a unique amino terminal domain that determines specificity
and functional diversity [22]. Many different ligands were
found to be bound to the annexin family and this associates
them with numerous mechanisms by which annexin 1
potentially can be linked to malignancy. A tissue-specific
Annexin 1 in urothelial carcinoma 149manner of annexin 1 was found in human tissue. Very low or
absent expression of annexin 1 was found in brain, muscle,
and liver tissue; moderate presence was noted in submax-
illary glands, prostate, thymus, and spleen; and the highest
expression were in lung and placenta [23]. Overexpression
and phosphorylation of annexin 1 were found both during
liver degeneration and transformation in antithrombin III
SV40 T large antigen transgenic mice, and in the tran-
scriptional and translational levels in tumorous and non-
tumorous areas of hepatocellular carcinoma [21,24].
Upregulation of annexin 1 was found to be associated with
increased synthesis of epidermal growth factor and conse-
quently with increased phosphorylation of EGF receptor.
Annexin 1 may also modulate the extracellular signal-
regulated kinase at an upstream site possibly by the key
signal components including the adaptor protein Grb2 [25].
Overexpression of annexin 1 might result in constitutive
activation of ERK1/2 kinase in macrophage [26]. The level
of annexin 1 expression was found to increase by 3 to 4
times when quiescent human diploid foreskin fibroblast
cells were stimulated to proliferate [27]. Such findings
imply that annexin 1 may participate in mitogenic signal
transduction and regulate cell growth, and they indicate
that annexin 1 may participate in cellular proliferation
directly or indirectly.
In bladder UC, some studies showed that the expression
of EGFR increased with T stage and tumor grade. These
studies found a marked upregulation in UC in situ rather
than in superficial noninvasive carcinoma but there was no
difference between UC in situ and infiltrating carcinoma,
nor was there such a difference when comparing primary
tumors and corresponding metastasis [28,29]. Similar find-
ings were found in our study. Because annexin 1 is
a substrate protein of EGFR, we might make the hypothesis
that the activated EGFR pathway promotes the annexin 1
upregulation and it is consequently associated with uro-
thelial cell malignancy transformation. When analyzing the
relation between annexin 1 and clinicopathological factors,
we found that high-grade types of UC were correlated with
positive annexin 1 expression; a similar finding was shown in
hepatocellular carcinoma [21]. These results suggest that
annexin 1 plays an important role in histological differen-
tiation in both UC and hepatocellular carcinoma. In addi-
tion, we also noticed that annexin 1 positivity varied in the
tumor stroma of both low- and high-grade UCs. However,
the significance of this positivity is still unclear and requires
further investigation.
In Taiwan, the incidence of upper UC is unusually high
[3]. Unlike bladder UC, few studies have discussed the
molecular indicators, such as the p53 mutation, EGFR or
erbB2, and MIB-1 [30e33]. Due to limited case numbers, the
conclusions of such studies were controversial. Annexin 1
expression was analyzed by comparing 133 upper UCs and
66 bladder UCs in our study and there was no statistical
difference between them. These results suggest that the
role of annexin 1 in carcinogenesis is similar in all urinary
tract diseases.
The present study shows that overexpression is frequent
in UC, and it may be one of the factors associated with
malignant transformation and histological differentiation.
However, the molecular mechanism needs to be investi-
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